These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37991630)

  • 1. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study.
    Omura J; Makanji Y; Tanabe N; Yu DY; Tan JY; Lim S; Kouhkamari MH; Casorso J; Wu DB; Bloomfield P
    Pulm Ther; 2023 Dec; 9(4):511-526. PubMed ID: 37991630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.
    Lau E; Kotlyar E; Makanji Y; Yu DY; Tan JY; Casorso J; Kouhkamari MH; Lim S; Wu DB; Bloomfield P
    J Med Econ; 2024; 27(1):596-604. PubMed ID: 38488130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
    Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
    PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Li J; Yang ZY; Wang S; Yuan P; Zhao QH; Gong SG; Qiu HL; Luo CJ; Li HT; Zhang R; Wu WH; Liu JM; Wang L; Liu SS; Jiang R
    Front Cardiovasc Med; 2022; 9():977110. PubMed ID: 36568539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
    Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J
    J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
    Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
    PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study.
    Cadenas-Menéndez S; Álvarez Vega P; Oterino Manzanas A; Alonso Lecue P; Roig Figueroa V; Bedate Díaz P; Ortiz de Saracho J; Cifrián Martínez JM
    Am J Cardiovasc Drugs; 2020 Oct; 20(5):481-487. PubMed ID: 31879844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis.
    Gatfield J; Mueller Grandjean C; Bur D; Bolli MH; Nayler O
    PLoS One; 2014; 9(9):e107809. PubMed ID: 25226600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan.
    Tynan T; Hird K; Hannon T; Gabbay E
    J Int Med Res; 2019 May; 47(5):2177-2186. PubMed ID: 30975046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
    Angus JA; Soeding PF; Hughes RJA; Wright CE
    Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension.
    Safdar Z; Thakur A; Frost A
    South Med J; 2017 Mar; 110(3):223-228. PubMed ID: 28257550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.
    Zhang YJ; Wang N; Gu ZC; Wei AH; Cheng AN; Fang SS; Du HL; Wang LZ; Zhang GQ
    Cardiovasc Diagn Ther; 2019 Jun; 9(3):239-249. PubMed ID: 31275814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study.
    Chen Y; Luo J; Chen J; Kotlyar E; Li Z; Chen W; Li J
    Front Pharmacol; 2021; 12():811700. PubMed ID: 35095523
    [No Abstract]   [Full Text] [Related]  

  • 19. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study.
    Amann U; Nadine Wentzell ; Kollhorst B; Haug U
    Reprod Toxicol; 2023 Aug; 119():108415. PubMed ID: 37245698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.